BCRX vs. MDGL, IONS, ALKS, FOLD, LGND, GERN, MNKD, DVAX, CLDX, and NVAX
Should you be buying BioCryst Pharmaceuticals stock or one of its competitors? The main competitors of BioCryst Pharmaceuticals include Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Geron (GERN), MannKind (MNKD), Dynavax Technologies (DVAX), Celldex Therapeutics (CLDX), and Novavax (NVAX). These companies are all part of the "biotechnology" industry.
BioCryst Pharmaceuticals vs.
BioCryst Pharmaceuticals (NASDAQ:BCRX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, community ranking, institutional ownership, media sentiment and risk.
BioCryst Pharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.36, meaning that its stock price is 136% less volatile than the S&P 500.
BioCryst Pharmaceuticals received 26 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. However, 67.80% of users gave Madrigal Pharmaceuticals an outperform vote while only 66.62% of users gave BioCryst Pharmaceuticals an outperform vote.
In the previous week, Madrigal Pharmaceuticals had 19 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 26 mentions for Madrigal Pharmaceuticals and 7 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.82 beat Madrigal Pharmaceuticals' score of 0.49 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.
Madrigal Pharmaceuticals has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -30.01%. BioCryst Pharmaceuticals' return on equity of 0.00% beat Madrigal Pharmaceuticals' return on equity.
85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 4.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 22.8% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
BioCryst Pharmaceuticals currently has a consensus price target of $15.17, suggesting a potential upside of 103.58%. Madrigal Pharmaceuticals has a consensus price target of $351.67, suggesting a potential upside of 19.76%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe BioCryst Pharmaceuticals is more favorable than Madrigal Pharmaceuticals.
BioCryst Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
BioCryst Pharmaceuticals beats Madrigal Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get BioCryst Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioCryst Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:BCRX) was last updated on 1/21/2025 by MarketBeat.com Staff
Free BCRX Stock Alerts